Patient Information
Ropivacaína B.Braun 10 mg/ml Injectable Solution EFG
Ropivacaína, hydrochloride
Read this entire leaflet carefully before you start taking this medicine, because it contains important information for you.
1. What is Ropivacaína B. Braun and for what it is used
2. What you need to know before starting Ropivacaína B. Braun
3. How you will be given Ropivacaína B. Braun
4. Possible side effects
5. Storage of Ropivacaína B. Braun
6. Contents of the container and additional information
The active ingredient is ropivacaína hydrochloride.
Ropivacaína B. Braun belongs to a group of medicines called local anesthetics (pain insensitizers).
Ropivacaína B. Braun injectable solution and for infusion is used in adults and adolescents (over 12 years) to anesthetize (insensitize) parts of your body during surgery, including cesarean section. It is used to prevent the appearance of pain or relieve pain.It may be used for
You should not be administered Ropivacaína B. Braun
If you are unsure if anything of the above affects you, speak with your doctor before they administer Ropivacaína B. Braun to you..
Warnings and precautions
Consult your doctor before starting to receive Ropivacaína B. Braun. Inform your doctor
Children
In children up to 12 years old, other concentrations (2 mg/ml, 5 mg/ml) may be more suitable.
Use of Ropivacaína B. Braun with other medications
Inform your doctor or pharmacist if you are using, have used recently or may need to take any other medication.
This is especially important with the following medications that may make the effects of Ropivacaína B. Braun more potent:
Prolonged use of ropivacaína should be avoided if you are being administered:
It may be suitable for you to receive Ropivacaína B. Brauneven while on these treatments.Your doctor needs to know this to be able to decide what is appropriate for you.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctorbefore they administer this medication to you.The safety of ropivacaína for use during pregnancy or breastfeeding has not been established.
Driving and operating machinery
Ropivacaína B. Braunmay cause drowsiness and alter your reaction time.After receiving this medication, do not drive, operate machinery or work in hazardous situations until the next day.
Ropivacaína B. Braun contains sodium
This medication contains 2.7mg of sodium (main component of table salt/for cooking) in each ml. This is equivalent to 0.14% of the maximum daily sodium intake recommended for an adult.
This medication will be administered by an expert doctor or under the supervision of one.
Ropivacaína B.Braun will be administered in the form of an injection. The part of the body where it will be applied will depend on the reason for which it is administered.Your doctor will administer this medication in one of the following locations:
While Ropivacaína B. Braun is being administered, you will be closely monitored by healthcare professionals.
This medication makes the nerves stop transmitting pain messages to the brain. You will no longer feel pain, heat, or cold in the area where it is used, but you may still feel other sensations such as pressure or contact.
Dosage
Your doctor will decide the dosage of Ropivacaína B. Braun to be administered. The dosage depends on your build, age, and physical condition.
If you are administered more Ropivacaína B. Braun than you should
Since this medication will be administeredbya doctor under carefully controlled conditions, it is unlikely that you will be administered a higher dose or miss a dose.
Severe side effects from receiving too much Ropivacaína B. Braun require special treatment. Your doctor is specialized to act in these situations.
The first signs of having received too much Ropivacaína B. Braun are usually the following:
If you receive too much Ropivacaína B. Braun, informimmediatelyyour doctorifyou experienceany of the following adverse effects:
Your doctor will stop administering this medication as soon as these signs appear to reduce the risk of severe adverse effects. This means that if you experience any of them or think you have received too much Ropivacaína B.Braun, you must inform your doctor immediately.
More severe side effects from receiving too much of this medication are,among others,speech problems, muscle spasms, tremors, convulsions, seizures, and loss of consciousness.
In case of acute toxicity, healthcare professionals will take the necessary corrective actions immediately.
If you have any other doubts about the use of thismedication, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
All medicines, including Ropivacaína B. Braun, can rarely cause allergic reactions such as anaphylaxis, including anaphylactic shock (can affect up to 1 person in every 1,000).. You must inform your doctor immediately if you experience any of the following symptoms after receiving this medicine:
Other possible side effects
Very common (can affect more than 1 person in every 10)
Common (can affect up to 1 person in every 10)
Possible side effects observed with other local anesthetics that may also be produced by Ropivacaína B. Braun
Children
In infants and children, the side effects are the same as in adults except for low blood pressure, which occurs less frequently in infants and children (affects up to 1 child in every 10) and feeling sick occurs more frequently in children (affects more than 1 child in every 10).
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through theSpanish System for Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and on the label after “CAD”. The expiration date is the last day of the month indicated.
Do not freeze.
Your doctor or pharmacist is responsible for the conservation of this medication. They are also responsible for the proper disposal of unused medication.
Composition of Ropivacaine B. Braun
The active ingredient is ropivacaine hydrochloride
1 ml of Ropivacaine B. Braun contains 10 mg of ropivacaine hydrochloride (in the form of ropivacaine hydrochloride monohydrate).
1 vial of 10 ml of injectable solution contains 100 mg of ropivacaine hydrochloride (in the form of ropivacaine hydrochloride monohydrate).
1 vial of 20 ml of injectable solution contains 200 mg of ropivacaine hydrochloride (in the form of ropivacaine hydrochloride monohydrate).
The other components are sodium chloride, hydrochloric acid 0.36% (for pH adjustment) and sodium hydroxide 0.4% (for pH adjustment), and water forinjectable preparations.
Appearance of the product and contents of the package
Ropivacaine B. Braun is a transparent and colorless injectable solution:
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
B. Braun Melsungen AG
Carl-Braun-Strasse 1Postal address:
34212 Melsungen, Germany34209 Melsungen, Germany
Phone: +49/5661/71-0
Fax: +49/5661/71-4567
This medicinal product is authorized in the member states of the European Economic Area with the following names:
Austria, Germany, Luxembourg:Ropivacain-HCl B.Braun10mg/ml Injektionslösung
Denmark:Ropivacain B.Braun 10 mg/ml
Finland:RopivacaineB.Braun10 mg/ml injektioneste, liuos
France:RopivacaineB. Braun10mg/ml, solution injectable enampoule
Italy:Ropivacaina B. Braun10mg/ml soluzione iniettabile
Sweden:Ropivacaine B. Braun 10 mg/ml injektionsvätska, lösning
Netherlands:Ropivacaïne HCl B. Braun 10 mg/ml, oplossing voorinjectie
Portugal:Ropivacaína B. Braun 10 mg/ml solução injetável
Spain:Ropivacaina B.Braun 10mg/ml solución inyectable
Last review date of this leaflet:10/2023.
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
------------------------------------------------------------------------------------------------------------------
This information is intended solely for healthcare professionals:
Administration form
A careful aspiration before and during injection is recommended to prevent intravascular injection. When a higher dose is to be injected, a lidocaine with adrenaline (epinephrine) test dose is advised. An accidental intravascular injection may be recognized by a temporary increase in heart rate and an accidental intrathecal injection by signs of spinal block.
Ropivacaine hydrochloride should be injected slowly or in increasing doses, at a rate of 25‑50mg/min, while constantly observing the patient's vital functions and maintaining verbal contact with him. If symptoms of toxicity appear, administration should be stopped immediately.
Warnings
Regional anesthesia procedures should always be performed in a properly equipped area with specialized personnel. Equipment and medications necessary for emergency monitoring and resuscitation should be available at all times.
Patients undergoing major blocks should be in optimal general condition and have an accessible intravenous route before the block procedure is performed.
The responsible physician should take necessary precautions to avoid intravascular injection (see section4.2 of the SmPC) and be adequately trained and familiar with the diagnosis and treatment of adverse effects, systemic toxicity, and other complications (see sections4.8 and 4.9 of the SmPC), such as accidental subarachnoid injection, which can cause high spinal block with apnea and hypotension. Seizures have occurred more frequently after brachial plexus block and epidural block. This is likely due to accidental intravascular injection or rapid absorption from the injection site.
Block of peripheral nerve trunks may involve administration of a large volume of local anesthetic in highly vascularized areas, often close to large vessels, where there is a greater risk of intravascular injection and/or rapid systemic absorption, which can lead to high plasma concentrations.
Patients with hypovolemia due to any cause may develop severe hypotension during epidural anesthesia, regardless of the local anesthetic used.
Handling
Disposal of unused medication and all materials that have come into contact with it will be carried out in accordance with local regulations.
For single use only.
The medication should be visually inspected before use.
Only use if the solution is transparent and colorless and if the container and its closure are intact
Validity period after the first opening of the container
From a microbiological point of view, unless the opening method excludes the risk of microbial contamination, the product should be used immediately.
If not used immediately, the times and conditions of storage during use are the responsibility of the user.
See the SmPC for instructions on incompatibilities and all relevant information on prescription.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.